[ad_1]
-
Oral report in The 63rd Annual Meeting of the American Society of Hematology Included in the results of the HERACLES Phase 2 trial in 24 patients with steroid-resistant grade III-IV gastrointestinal acute graft-versus-host disease (GI-aGvHD) and the sympathetic use program (early access program or EAP) of MaaT013 in France Results 52 patients with grade II-IV GI-aGvHD failed their previous treatment
-
In the HERACLES trial, the 28-day GI-overall response rate (GI-ORR) for MaaT013 was 38%, including 5 complete remissions (21%), and 58% in EAP, including 17 complete remissions (33%)
-
The best GI-ORR on day 28 in HERACLES is 54% and 67% in EAP
-
The 12-month overall survival rate for patients who responded to treatment was 44% in HERACLES and 59% in EAP
-
The key phase 3 clinical trial of MaaT013 in aGvHD is starting
The company will host an investor webcast on Monday, December 13th at 6 pm Central European Time:
In order to discuss the clinical data of the MaaT013 program and provide company updates, MaaT Pharma will host an investor webcast on Monday, December 13, 2021 at 6:00 PM Central European Time / 12:00 PM US Eastern Time. To register and access the webcast, click here. A rebroadcast of the webcast will be provided shortly after the webcast ends and archived on the MaaT Pharma website for at least 90 days.
Regulatory News:
Mart Pharmaceutical (EURONEEXT: MAAT——”Company”), a French clinical-stage biotechnology company, is also a pioneer in the development of microbiome-based ecosystem therapy, dedicated to improving the survival outcomes of cancer patients, Today announced additional data from its phase 2 clinical trial HERACLES (NCT03359980) And its Compassionate Use (EAP) program for MaaT013 in France, its high-rich, high-diversity lead microbiome Ecosystem Therapy (MET). Data show that in patients with gastrointestinal involvement acute graft-versus-host disease (GI-aGvHD) after hematopoietic cell transplantation, MaaT013 treatment shows a promising objective gastrointestinal response rate (GI-ORR)1 In two groups. The primary endpoints of GI-ORR on day 28 for HERACLES patients were 38% and 58%, respectively. In HERACLES and EAP patients, the secondary end points of optimal GI-ORR on day 28 were 54% and 67%, respectively. The clinical benefit of MaaT013 administration has a positive effect on the overall survival (OS) rate of patients who respond to treatment: HERACLES patients have an overall survival rate of 44% at 12 months, and EAP patients 59%. MaaT013 is also well tolerated in this group of patients with severely impaired immune function.
Data is provided verbally Dr. Florent…
The full story can be found on Benzinga.com
[ad_2]
Source link
